GlassScriptPhysician profile
Erik S Crook
NPI 1659449544
$3,171.24
in general payments reported to CMS, 2019-2025
27 companies · $849 in 2025
The $849 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $14.05 · 2022: $454 · 2023: $718 · 2024: $940 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,507.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $463.81 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $439.00 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $420.73 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $251.50 | 2022-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $207.84 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.16 | 2019-2025 | Jardiance |
| Amgen INC. | $197.29 | 2022-2025 | Krystexxa, Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $194.74 | 2022-2025 | |
| Astellas Pharma US INC | $125.07 | 2019-2025 | Veozah |
| Abbott Laboratories | $95.74 | 2023-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $77.76 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.95 | 2024-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $64.03 | 2022-2023 | |
| Dynavax Technologies Corporation | $52.06 | 2024 | Heplisav-B |
| Glaxosmithkline, LLC. | $45.28 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $37.61 | 2025 | Rosa |
| Shield Therapeutics INC | $29.34 | 2025 | |
| Phathom Pharmaceuticals, INC. | $28.37 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $26.68 | 2022-2023 | Camzyos |
| Sumitomo Pharma America, INC. | $22.03 | 2025 | Gemtesa |
| Daiichi Sankyo INC. | $19.85 | 2022 | |
| Gilead Sciences, INC. | $19.78 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.58 | 2023 | Trintellix |
| Corcept Therapeutics | $14.94 | 2024 | Korlym |
| Medtronic, INC. | $14.63 | 2025 | Intellis Adaptivestim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.34 | 2024 | Caplyta |
| Inari Medical, INC. | $13.13 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Crook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.